Aquestive Therapeutics Inc (NAS:AQST)
$ 3.27 0.18 (5.83%) Market Cap: 297.70 Mil Enterprise Value: 220.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

Aquestive Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 12:00PM GMT
Release Date Price: $4.36 (-1.13%)
Carvey Leung
Cantor Fitzgerald - Analyst

Good morning, everyone. My name is Carvey Leung, an associate on Louise Chen's large-cap and biopharma equity research team here at Cantor. Thank you for joining us today for our virtual fireside chat with Aquestive Therapeutics.

Aquestive is a pharma company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally developed proprietary product to date, Sympazan oral film, has a commercial proprietary pipeline focused on the treatment of diseases of the central nervous system and other unmet needs. And the Company is also developing orally administered complex molecules to provide alternatives to invasively administered standard of care treatments.

We are very excited to have Keith Kendall, CEO; Ernie Toth, CFO; and Dan Barber, COO of Aquestive with us today to discuss the Company.

Questions & Answers

Carvey Leung
Cantor Fitzgerald - Analyst

Well, first of all, welcome. And for the investors that are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot